{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:54:04Z","timestamp":1794351244484,"version":"4.9.0"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004329","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000}}],"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI068614"],"award-info":[{"award-number":["AI068614"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI068614"],"award-info":[{"award-number":["AI068614"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI068614"],"award-info":[{"award-number":["AI068614"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI068614"],"award-info":[{"award-number":["AI068614"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI068614"],"award-info":[{"award-number":["AI068614"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068635"],"award-info":[{"award-number":["UM1 AI068635"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068635"],"award-info":[{"award-number":["UM1 AI068635"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068635"],"award-info":[{"award-number":["UM1 AI068635"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068635"],"award-info":[{"award-number":["UM1 AI068635"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068618"],"award-info":[{"award-number":["UM1 AI068618"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068618"],"award-info":[{"award-number":["UM1 AI068618"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068618"],"award-info":[{"award-number":["UM1 AI068618"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI069412"],"award-info":[{"award-number":["UM1 AI069412"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI069412"],"award-info":[{"award-number":["UM1 AI069412"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 RR025758"],"award-info":[{"award-number":["UL1 RR025758"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P30 AI50410"],"award-info":[{"award-number":["P30 AI50410"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI069423"],"award-info":[{"award-number":["UM1 AI069423"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068619"],"award-info":[{"award-number":["UM1 AI068619"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068619"],"award-info":[{"award-number":["UM1 AI068619"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068617"],"award-info":[{"award-number":["UM1 AI068617"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068613"],"award-info":[{"award-number":["UM1 AI068613"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UM1 TR004406"],"award-info":[{"award-number":["UM1 TR004406"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Broadly neutralizing antibodies (bnAbs) are a promising approach for HIV-1 prevention. In the Antibody Mediated Prevention (AMP) trials, a CD4-binding site targeting bnAb, VRC01, administered intravenously (IV), demonstrated 75% prevention efficacy against highly neutralization-sensitive viruses but was ineffective against less sensitive viruses. VRC07-523LS is a next-generation bnAb targeting the CD4-binding site and was engineered for increased neutralization breadth and half-life. We conducted a multicenter, randomized, partially blinded Phase I clinical trial to evaluate the safety and serum concentrations of VRC07-523LS, administered in multiple doses and routes to healthy adults without HIV.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>Participants were recruited between 2 February 2018 and 9 October 2018. A total of 124 participants were randomized to receive 5 VRC07-523LS administrations via IV (T1: 2.5 mg\/kg, T2: 5 mg\/kg, T3: 20 mg\/kg), subcutaneous (SC) (T4: 2.5 mg\/kg, T5: 5 mg\/kg), or intramuscular (IM) (T6: 2.5 mg\/kg or P6: placebo) routes at 4-month intervals. Participants and site staff were blinded to VRC07-523LS versus placebo for the IM group, while all other doses and routes were open-label. Safety data were collected for 144 weeks following the first administration. VRC07-523LS serum concentrations were measured by ELISA through Day 112 in all participants and by binding antibody multiplex assay (BAMA) thereafter in 60 participants (10 per treatment group) through Day 784. Compartmental population pharmacokinetic (PK) analyses were conducted to evaluate the VRC07-523LS serum PK. Neutralization activity was measured in a TZM-bl assay and antidrug antibodies (ADAs) were assayed using a tiered bridging assay testing strategy.<\/jats:p>\n<jats:p>Injections and infusions were well tolerated, with mild pain or tenderness reported commonly in the SC and IM groups, and mild to moderate erythema or induration reported commonly in the SC groups. Infusion reactions were reported in 3 of 20 participants in the 20 mg\/kg IV group. Peak geometric mean (GM) concentrations (95% confidence intervals [95% CIs]) following the first administration were 29.0 \u03bcg\/mL (25.2, 33.4), 58.5 \u03bcg\/mL (49.4, 69.3), and 257.2 \u03bcg\/mL (127.5, 518.9) in T1-T3 with IV dosing; 10.8 \u03bcg\/mL (8.8, 13.3) and 22.8 \u03bcg\/mL (20.1, 25.9) in T4-T5 with SC dosing; and 16.4 \u03bcg\/mL (14.7, 18.2) in T6 with IM dosing. Trough GM (95% CIs) concentrations immediately prior to the second administration were 3.4 \u03bcg\/mL (2.5, 4.6), 6.5 \u03bcg\/mL (5.6, 7.5), and 27.2 \u03bcg\/mL (23.9, 31.0) with IV dosing; 0.97 \u03bcg\/mL (0.65, 1.4) and 3.1 \u03bcg\/mL (2.2, 4.3) with SC dosing, and 2.6 \u03bcg\/mL (2.05, 3.31) with IM dosing. Peak VRC07-523LS serum concentrations increased linearly with the administered dose. At a given dose, peak and trough concentrations, as well as serum neutralization titers, were highest in the IV groups, reflecting the lower bioavailability following SC and IM administration. A single participant was found to have low titer ADA at a lone time point. VRC07-523LS has an estimated mean half-life of 42 days across all doses and routes (95% CI: 40.5, 43.5), over twice as long as VRC01 (15 days).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>VRC07-523LS was safe and well tolerated across a range of doses and routes and is a promising long-acting bnAb for inclusion in HIV-1 prevention regimens.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Trial registration<\/jats:title>\n<jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\/\" xlink:type=\"simple\">ClinicalTrials.gov\/<\/jats:ext-link> <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03387150\" xlink:type=\"simple\">NCT03387150<\/jats:ext-link> (posted on 21 December 2017).<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004329","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T19:36:45Z","timestamp":1719257805000},"page":"e1004329","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127\/HPTN 087): A Phase I randomized clinical trial"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0817-9370","authenticated-orcid":true,"given":"Stephen R.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia L.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly T.","family":"Karuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ollivier","family":"Hyrien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8317-7685","authenticated-orcid":true,"given":"Timothy","family":"Skalland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7460-733X","authenticated-orcid":true,"given":"Kenneth H.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena E.","family":"Sobieszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Goepfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"del Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3651-2721","authenticated-orcid":true,"given":"Guiseppe","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carissa","family":"Karg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonglin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0442-2639","authenticated-orcid":true,"given":"Huiyin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8640-6623","authenticated-orcid":true,"given":"Carmen A.","family":"Paez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A. G.","family":"Baumblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5476-7632","authenticated-orcid":true,"given":"Laura L.","family":"Polakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wairimu","family":"Chege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Janto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunda","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-5819","authenticated-orcid":true,"given":"Julie","family":"Dumond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-3476","authenticated-orcid":true,"given":"Margaret E.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian B.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Flach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6501-0440","authenticated-orcid":true,"given":"Estelle","family":"Piwowar-Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2009-3270","authenticated-orcid":true,"given":"Kelly","family":"Seaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8076-1931","authenticated-orcid":true,"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-6319","authenticated-orcid":true,"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5293-4695","authenticated-orcid":true,"given":"John R.","family":"Mascola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the HVTN 127\/HPTN 087 Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"pmed.1004329.ref001","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev-med-110918-034551","article-title":"Prevention of HIV Transmission and the HPTN 052 Study.","volume":"71","author":"MS Cohen","year":"2020","journal-title":"Annu Rev Med."},{"key":"pmed.1004329.ref002","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"S Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"key":"pmed.1004329.ref003","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women","volume":"385","author":"RJ Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"pmed.1004329.ref004","author":"UNAIDS","year":"2023","journal-title":"Global HIV & AIDS statistics\u2014Fact sheet"},{"key":"pmed.1004329.ref005","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1186\/s12889-020-09785-0","article-title":"Willingness to use HIV prevention methods among vaccine efficacy trial participants in Soweto, South Africa: discretion is important.","volume":"20","author":"F Laher","year":"2020","journal-title":"BMC Public Health."},{"key":"pmed.1004329.ref006","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev-med-110118-045506","article-title":"Broadly Neutralizing Antibodies for HIV Prevention.","volume":"71","author":"ST Karuna","year":"2020","journal-title":"Annu Rev Med."},{"key":"pmed.1004329.ref007","doi-asserted-by":"crossref","first-page":"712122","DOI":"10.3389\/fimmu.2021.712122","article-title":"Broadly Neutralizing Antibodies for HIV-1 Prevention.","volume":"12","author":"SR Walsh","year":"2021","journal-title":"Front Immunol."},{"key":"pmed.1004329.ref008","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition","volume":"384","author":"L Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"pmed.1004329.ref009","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/s41591-022-01953-6","article-title":"Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition","volume":"28","author":"PB Gilbert","year":"2022","journal-title":"Nat Med"},{"key":"pmed.1004329.ref010","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo","volume":"88","author":"RS Rudicell","year":"2014","journal-title":"J Virol"},{"key":"pmed.1004329.ref011","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"SY Ko","year":"2014","journal-title":"Nature"},{"key":"pmed.1004329.ref012","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"J Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"key":"pmed.1004329.ref013","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial","volume":"6","author":"MR Gaudinski","year":"2019","journal-title":"Lancet HIV"},{"key":"pmed.1004329.ref014","author":"World Health Organization","year":"2023","journal-title":"WHO preferred product characteristics for monoclonal antibodies for HIV prevention"},{"key":"pmed.1004329.ref015","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2013.07.003","article-title":"Behavioral risk assessment in HIV Vaccine Trials Network (HVTN) clinical trials: a qualitative study exploring HVTN staff perspectives.","volume":"31","author":"MP Andrasik","year":"2013","journal-title":"Vaccine"},{"key":"pmed.1004329.ref016","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"BF Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"pmed.1004329.ref017","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1073\/pnas.1301456110","article-title":"Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG","volume":"110","author":"GD Tomaras","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pmed.1004329.ref018","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.","volume":"82","author":"GD Tomaras","year":"2008","journal-title":"J Virol"},{"key":"pmed.1004329.ref019","doi-asserted-by":"crossref","first-page":"228ra239","DOI":"10.1126\/scitranslmed.3007730","article-title":"Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.","volume":"6","author":"NL Yates","year":"2014","journal-title":"Sci Transl Med."},{"key":"pmed.1004329.ref020","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","volume":"485","author":"DC Montefiori","year":"2009","journal-title":"Methods Mol Biol"},{"key":"pmed.1004329.ref021","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","journal-title":"J Immunol Methods"},{"key":"pmed.1004329.ref022","doi-asserted-by":"crossref","first-page":"e1011469","DOI":"10.1371\/journal.ppat.1011469","article-title":"Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.","volume":"19","author":"NN Mkhize","year":"2023","journal-title":"PLoS Pathog"},{"key":"pmed.1004329.ref023","doi-asserted-by":"crossref","first-page":"112764","DOI":"10.1016\/j.jim.2020.112764","article-title":"Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies","volume":"479","author":"P Bharadwaj","year":"2020","journal-title":"J Immunol Methods"},{"key":"pmed.1004329.ref024","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1198\/sbr.2009.0008","article-title":"Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine Development","volume":"1","author":"Y Huang","year":"2009","journal-title":"Stat Biopharm Res"},{"key":"pmed.1004329.ref025","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1214\/14-EJS890","article-title":"A note on BIC in mixed-effects models.","volume":"8","author":"M Delattre","year":"2014","journal-title":"Electron J Statist."},{"key":"pmed.1004329.ref026","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/psp4.12500","article-title":"Efficient Pharmacokinetic Modeling Workflow With the MonolixSuite: A Case Study of Remifentanil.","volume":"9","author":"P Traynard","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"pmed.1004329.ref027","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/QAI.0000000000002892","article-title":"Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials.","volume":"89","author":"S Takuva","year":"2022","journal-title":"J Acquir Immune Defic Syndr."},{"key":"pmed.1004329.ref028","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/QAI.0000000000002369","article-title":"Social Impacts Among Participants in HIV Vaccine Trial Network (HVTN) Preventive HIV Vaccine Trials.","volume":"84","author":"MP Andrasik","year":"2020","journal-title":"J Acquir Immune Defic Syndr."},{"key":"pmed.1004329.ref029","doi-asserted-by":"crossref","first-page":"103203","DOI":"10.1016\/j.ebiom.2020.103203","article-title":"Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials.","volume":"64","author":"Y Huang","year":"2021","journal-title":"EBioMedicine"},{"key":"pmed.1004329.ref030","doi-asserted-by":"crossref","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.","volume":"15","author":"MR Gaudinski","year":"2018","journal-title":"PLoS Med."},{"key":"pmed.1004329.ref031","doi-asserted-by":"crossref","first-page":"e1002435","DOI":"10.1371\/journal.pmed.1002435","article-title":"Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.","volume":"14","author":"KH Mayer","year":"2017","journal-title":"PLoS Med."},{"key":"pmed.1004329.ref032","doi-asserted-by":"crossref","first-page":"e0219142","DOI":"10.1371\/journal.pone.0219142","article-title":"Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10\u20131074 in healthy adults: A randomized, phase 1 study.","volume":"14","author":"YZ Cohen","year":"2019","journal-title":"PLoS ONE"},{"key":"pmed.1004329.ref033","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","article-title":"Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial","volume":"27","author":"KE Stephenson","year":"2021","journal-title":"Nat Med"},{"key":"pmed.1004329.ref034","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","article-title":"Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial","volume":"28","author":"B Julg","year":"2022","journal-title":"Nat Med"},{"key":"pmed.1004329.ref035","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Y Bar-On","year":"2018","journal-title":"Nat Med"},{"key":"pmed.1004329.ref036","doi-asserted-by":"crossref","first-page":"e653","DOI":"10.1016\/S2352-3018(23)00140-6","article-title":"Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10\u20131074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial","volume":"10","author":"ME Sobieszczyk","year":"2023","journal-title":"Lancet HIV"},{"key":"pmed.1004329.ref037","doi-asserted-by":"crossref","first-page":"e1005520","DOI":"10.1371\/journal.ppat.1005520","article-title":"Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.","volume":"12","author":"K Wagh","year":"2016","journal-title":"PLoS Pathog."},{"key":"pmed.1004329.ref038","doi-asserted-by":"crossref","first-page":"e042247","DOI":"10.1136\/bmjopen-2020-042247","article-title":"Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial","volume":"10","author":"S Mahomed","year":"2020","journal-title":"BMJ Open"},{"key":"pmed.1004329.ref039","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(23)00003-6","article-title":"Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial.","volume":"10","author":"S Mahomed","year":"2023","journal-title":"Lancet HIV"},{"key":"pmed.1004329.ref040","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2217\/imt.14.50","article-title":"Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer","volume":"6","author":"B Melichar","year":"2014","journal-title":"Immunotherapy"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004329","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T17:46:27Z","timestamp":1721151987000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pmed.1004329","asserted-by":"object"}],"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.g001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.g002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.g003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.g004","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.g005","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.g006","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.g007","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.t001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.t002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.s002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.s003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.s004","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.s005","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.s006","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.s007","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.s008","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.s009","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.s010","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.s011","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.s012","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pmed.1004329.s013","asserted-by":"subject"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]}}}